AH 11110A: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 9907616 |
| MeSH ID | M0397643 |
| Synonym |
|---|
| ah 11110, >98% (hplc), solid |
| ah 11110 hydrochloride |
| ah 11110 |
| 179388-65-9 |
| 4-imino-1-(2-phenylphenoxy)-4-piperidinebutan-2-ol hydrochloride |
| ah-11110 |
| gtpl8461 |
| 4-imino-1-(2-phenylphenoxy)-4-piperidin-1-ylbutan-2-ol hydrochloride |
| AKOS024458726 |
| DTXSID90432694 |
| SR-01000597846-1 |
| sr-01000597846 |
| Q27074354 |
| 1-piperidinepropanol, alpha-[([1,1'-biphenyl]-2-yloxy)methyl]-gamma-imino-, hydrochloride (1:1) |
| ah 11110a |
| ah11110a;ah-11110a |
| 4-imino-1-(2-phenylphenoxy)-4-piperidin-1-ylbutan-2-ol;hydrochloride |
| 1-piperidinepropanol,a-[([1,1'-biphenyl]-2-yloxy)methyl]-g-imino-,hydrochloride(1:1) |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Additionally, AH11110A enhanced the general contractility of rat vas deferens, produced a bell-shaped dose-response curve of vasodilation in perfused rat kidney, and its antagonism in most other tissues was not simply competitive." | ( Failure of AH11110A to functionally discriminate between alpha(1)-adrenoceptor subtypes A, B and D or between alpha(1)- and alpha(2)-adrenoceptors. Eltze, M; Grebe, T; König, H; Ullrich, B, 2001) | 0.31 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1346000 | Human alpha1B-adrenoceptor (Adrenoceptors) | 1996 | The Journal of pharmacology and experimental therapeutics, Jul, Volume: 278, Issue:1 | Structure activity relationships of a series of buspirone analogs at alpha-1 adrenoceptors: further evidence that rat aorta alpha-1 adrenoceptors are of the alpha-1D-subtype. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||